Stayble Therapeutics AB (STU:4K4) FCF Yield % : -275.23 (As of May. 14, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Stayble Therapeutics AB's Trailing 12-Month Free Cash Flow is €-1.83 Mil, and Market Cap is €0.65 Mil. Therefore, Stayble Therapeutics AB's FCF Yield % for today is -275.23%.

The historical rank and industry rank for Stayble Therapeutics AB's FCF Yield % or its related term are showing as below:

STU:4K4' s FCF Yield % Range Over the Past 10 Years
Min: -297.72 Med: 0 Max: 0
Current: -275.23

STU:4K4's FCF Yield % is ranked worse than
93.89% of 1554 companies
in the Biotechnology industry
Industry Median: -14.38 vs STU:4K4: -275.23

Stayble Therapeutics AB's FCF Margin % for the quarter that ended in Sep. 2023 was 0.00%.

Stayble Therapeutics AB FCF Yield % Historical Data

The historical data trend for Stayble Therapeutics AB's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB FCF Yield % Chart

Stayble Therapeutics AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Yield %

Get a 7-Day Free Trial

-48.51

Stayble Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
FCF Yield %	Get a 7-Day Free Trial															-50.82	-34.11	-107.65	-50.34	-10.95

Competitive Comparison of Stayble Therapeutics AB's FCF Yield %

For the Biotechnology subindustry, Stayble Therapeutics AB's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stayble Therapeutics AB's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's FCF Yield % falls into.

Stayble Therapeutics AB FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Stayble Therapeutics AB's FCF Yield % for the fiscal year that ended in Dec. 2022 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-2.264	/	4.6669152
	=	-48.51%

Stayble Therapeutics AB's annualized FCF Yield % for the quarter that ended in Sep. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-0.364	*	4	/	13.2910571
	=	-10.95%

Stayble Therapeutics AB FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Stayble Therapeutics AB FCF Yield % Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Stayble Therapeutics AB (STU:4K4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

STABL:Sweden 4K4:Germany

Address

Medicinaregatan 8a, Gothenburg, SWE, SE-413 90

Website

http://www.staybletherapeutics.com

Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines